Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ Reduction
Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), William J. Greenlee, Yusheng Wu, Leonard Favreau(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sarah W. Li, Eric J. Gilbert, Eric M. Parker(University of New Hampshire), Matthew Kennedy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dawit Tadesse(Ligand Pharmaceuticals (United States)), Reshma Kuvelkar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Orth, Kathleen Cox(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared N. Cumming(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeffrey Misiaszek, Jack D. Scott(Merck & Co., Inc., Rahway, NJ, USA (United States)), Johannes Voigt, Robert A. Hodgson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xia Chen(First People's Hospital of Foshan), Zhaoning Zhu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tao Guo(WuXi AppTec (China)), Corey Strickland(Merck & Co., Inc., Rahway, NJ, USA (United States)), Suresh Babu(Ligand Pharmaceuticals (United States)), Liwu Hong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lynn A. Hyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brian A. McKittrick(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rachael Hunter(Ligand Pharmaceuticals (United States)), Chunli Huang(Shanghai Jiao Tong University)
Cited by 99
Related Papers
Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation
|Journal of Biological Chemistry|2004|716
Protein misfolding in neurodegenerative diseases: implications and strategies
|Translational Neurodegeneration|2017|671
Transcriptional regulation of the rat NAD(P)H:quinone reductase gene
|Journal of Biological Chemistry|1991|500
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
|Journal of Pharmacology and Experimental Therapeutics|2015|336